Overview

Evaluate the Efficacy, Safety and Tolerability of HLX26 and HLX10 in Patients With Metastatic Colorectal Carcinoma That Have Received 3 Prior Lines of Therapy

Status:
Not yet recruiting

Trial end date:
2023-11-23

Target enrollment:

Participant gender:

Summary

This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins